Skip to Main Content

Paper Details

Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist.
J Clin Med
7
2023
CKD, Chronic kidney disease, Finerenone, SGLT2is, cardiovascular disease, cardiovascular events, diabetes, diabetes mellitus, end-stage kidney disease, finerenone, glucose, kidney and heart disease, mineralocorticoid receptor, patients, renal failure, sodium-, sodium-glucose cotransporter 2, type 2 diabetes, type 2 diabetes mellitus
Author NameAffiliation
Claudio RoncoInternational Renal Research Institute (IRRIV), S. Bortolo Hospital
Antonio Bellasi
Antonio Bellasi
  • 1 - 3

Datasets

Release 1.2